RNF43 and pancreatic neoplasm: Here, to identify mechanisms that confer resistance to upstream Wnt pathway inhibitors in RNF43-mutant pancreatic cancers, we performed in vivo CRISPR screens during PORCN inhibitor therapy in mice bearing RNF43-mutant pancreatic tumor xenografts.